Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
July 26, 2024 Presentation

Aptose Corporate Presentation July 2024

Aptose Corporate Presentation July 2024: View Presentation
May 3, 2024 Presentation

Aptose Corporate Presentation May 2024

Aptose Corporate Presentation May 2024: View Presentation
December 26, 2023 Presentation

Aptose Corporate Presentation December 2023

Aptose Corporate Presentation December 2023: View Presentation
December 9, 2023 Presentation

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Presentation
October 30, 2023 Presentation

Tuspetinib Clinical Update and KOL Data Review

Tuspetinib Clinical Update and KOL Data Review: View Presentation
September 11, 2023 Presentation

Aptose Corporate Presentation September 2023

Aptose Corporate Presentation September 2023: View Presentation
June 10, 2023 Presentation

Aptose Interim Clinical Update

Aptose Interim Clinical Update: View Presentation
April 13, 2023 Presentation

Aptose Corporate Presentation April 2023

Aptose Corporate Presentation April 2023: View Presentation
January 6, 2023 Presentation

Aptose Corporate Presentation January 2023

Aptose Corporate Presentation January 2023: View Presentation